SecBot SecBot
6-K ·Filed Sep 24, 2026

CLGN

CollPlant Biotechnologies Ltd
NEUTRAL
Impact 4/10
Horizonmonths Processed1mo ago SEC0001213900-26-102965
Notable filing: 6-K
Actionable Insight • Neutral

Monitor for any future announcements of physical LPU hardware milestones or commercial partnerships. The emulation results are promising but the technology remains pre-revenue and pre-product — no near-term revenue impact.

DirectionNeutral
Confidencemedium
Horizonmonths
Latest settled — T+20d
CLGN ▼ -12.14% at T+20d
NEUTRAL call -12.14% · α vs SPY -11.72% · entry $4.12 → $3.62
Next anchor: T+60d in 7w
Latest observation: T+21 -7.94% FF3 residual α
Entry = T+0 close
Sep 24, 2026
via day close
T+1d
+3.16%
call +3.16% · α +2.61%
$4.25
settled 5w ago
T+5d
-13.35%
call -13.35% · α -12.93%
$3.57
settled 27d ago
T+20d
-12.14%
call -12.14% · α -11.72%
$3.62
settled 6d ago
T+60d
Pending
in 7w

Price Chart

Loading chart...

Executive Summary

CollPlant's subsidiary LightSolver published peer-reviewed research with HLRS demonstrating that its photonic LPU architecture could accelerate solving large sparse linear systems by 40x to over 80,000x vs GPU algorithms. This is a validation milestone for the photonic computing technology but remains at the emulation/projection stage with no revenue or product commercialization timeline.

Key Facts

  • LightSolver's LPU architecture projected 40x to >80,000x time-to-solution acceleration vs GPU algorithms in benchmarked problems
  • Research published in proceedings of 23rd ACM International Conference on Computing Frontiers
  • Study used an emulator of the LPU architecture, not physical hardware
  • Joint research with High-Performance Computing Center Stuttgart (HLRS)
  • CollPlant operates at intersection of deep-tech computing (LightSolver) and regenerative medicine (rhCollagen)

Financial Impact

No financial figures disclosed; research-stage technology with no revenue or commercialization timeline

Risk Factors

  • Projected performance from emulators may not replicate in physical hardware
  • No commercialization timeline or revenue from photonic computing
  • Company has dual focus on biotech and computing, which may dilute resources and investor attention

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-102965
Document: ea0306536-6k_collplant.htm0001213900-26-102965
Document: 0001213900-26-102965-index-headers.html0001213900-26-102965
Document: 0001213900-26-102965-index.html0001213900-26-102965
Document: 0001213900-26-102965.txt0001213900-26-102965
21 reports for CLGN
Performance horizon
100% Hit rate @ T+1 9 of 9 directional calls Went positive at some point 9 of 9 best @ T+60▲ +25.17%May 29, 2026
Filters
Rows
Reports for CLGN — sortable, filterable
TypeNow
Oct 27, 2026
today
144
NEUTRAL ★ 2/10
$3.78awaiting T+1—$3.75 (−0.79%)
Oct 19, 2026
8d ago
3
NEUTRAL ★ 2/10
$3.88 $3.76▼ −3.22%▼ −3.75%$3.75 (−3.35%)
Oct 15, 2026
12d ago
6-K
BEARISH ★ 6/10
$3.68 $3.63▲ +1.49%▲ +0.39%$3.75 (−1.90%)
Oct 9, 2026
18d ago
6-K
BEARISH ★ 5/10
$4.02 $3.91▲ +2.74%▲ +2.72%$3.75 (+6.72%)
Oct 8, 2026
19d ago
SC 13G
NEUTRAL ★ 3/10
$3.97 $3.51▼ −11.59%▼ −12.19%$3.75 (−5.54%)
Oct 8, 2026
19d ago
SC 13D/A
NEUTRAL ★ 3/10
$3.97 $3.51▼ −11.59%▼ −12.19%$3.75 (−5.54%)
Oct 6, 2026
21d ago
6-K
NEUTRAL ★ 3/10
$3.39 $3.46▲ +2.06%▲ +2.30%$3.75 (+10.62%)
Sep 30, 2026
27d ago
6-K
BEARISH ★ 7/10
$3.57 $3.46▲ +3.08%▲ +3.82%$3.75 (−5.04%)
Sep 30, 2026
27d ago
Press Release
BEARISH ★ 5/10
$3.57 $3.46▲ +3.08%▲ +3.82%$3.75 (−5.04%)
Sep 24, 2026
4w ago
6-K
NEUTRAL ★ 4/10
$4.12 $4.25▲ +3.16%▲ +2.61%$3.75 (−8.98%)
Showing 10 of 21

US Market Status

Market Closed — Opens Thu (12h 11m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 24, 2026